Myelodysplastic Syndrome
News
Luspatercept reduced transfusion burden in MDS patients
SAN DIEGO—Results of the randomized, phase 3 Medalist trial show that the erythroid maturation agent luspatercept can reduce transfusion burden in...
Conference Coverage
MEDALIST: Erythroid maturation agent reduced transfusion burden in MDS
SAN DIEGO – Luspatercept also showed promise in a phase 3 trial including adults with beta-thalassemia.
Conference Coverage
Your guide to ASH 2018: Abstracts to watch
News
FDA approves emapalumab for primary HLH
Emapalumab (Gamifant) is expected to be available in the U.S. in the first quarter of 2019.
News
FDA approves generic decitabine for MDS
The U.S. Food and Drug Administration has approved Lupin’s decitabine product, a generic version of Otsuka Pharmaceutical Co.
News
Financial burden of blood cancers in the U.S.
An analysis of more than 2,000 U.S.
News
Combo worsens platelet recovery in MDS
Results from the phase 3 SUPPORT trial suggest there is no role for the combination of eltrombopag and azacitidine in patients with intermediate-...
Conference Coverage
When is it CMML?
DUBROVNIK, CROATIA – Dr. Nadira Durakovic offers her tips for differentiating between CMML and other look-alike disorders.
News
‘Intense’ end-of-life care may be common in HSCT recipients
Patients who die within a year of allogeneic hematopoietic stem cell transplant (HSCT) tend to receive “medically intense” end-of-life care, an...
News
Researchers develop genetics-based prognostic tool for MDS
Researchers have developed a new risk model for primary myelodysplastic syndromes (MDS) that integrates genetic and clinical information. The...
News
Sequencing informs prognosis after HSCT in MDS
Gene sequencing early after transplant may provide important prognostic information in patients with myelodysplastic syndromes (MDS), according to...